330 related articles for article (PubMed ID: 33691750)
21. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
[TBL] [Abstract][Full Text] [Related]
22. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.
Wu X; Ge H; Lemon B; Weiszmann J; Gupte J; Hawkins N; Li X; Tang J; Lindberg R; Li Y
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14379-84. PubMed ID: 19706524
[TBL] [Abstract][Full Text] [Related]
23. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
Li X; Lu W; Kharitonenkov A; Luo Y
J Intern Med; 2024 Mar; 295(3):292-312. PubMed ID: 38212977
[TBL] [Abstract][Full Text] [Related]
24. Salvianolic acid B blocks hepatic stellate cell activation via FGF19/FGFR4 signaling.
Tian S; Chen M; Wang B; Han Y; Shang H; Chen J
Ann Hepatol; 2021; 20():100259. PubMed ID: 32980439
[TBL] [Abstract][Full Text] [Related]
25. Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation.
He Q; Huang W; Liu D; Zhang T; Wang Y; Ji X; Xie M; Sun M; Tian D; Liu M; Xia L
Theranostics; 2021; 11(12):5759-5777. PubMed ID: 33897880
[No Abstract] [Full Text] [Related]
26. Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma.
Shin JY; Ahn SM
J Transl Med; 2021 Apr; 19(1):138. PubMed ID: 33794926
[TBL] [Abstract][Full Text] [Related]
27. FGF19-
Raja A; Park I; Haq F; Ahn SM
Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
[TBL] [Abstract][Full Text] [Related]
28. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
[TBL] [Abstract][Full Text] [Related]
29. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
30. Small hepatitis B virus surface antigen promotes malignant progression of hepatocellular carcinoma via endoplasmic reticulum stress-induced FGF19/JAK2/STAT3 signaling.
Wu S; Ye S; Lin X; Chen Y; Zhang Y; Jing Z; Liu W; Chen W; Lin X; Lin X
Cancer Lett; 2021 Feb; 499():175-187. PubMed ID: 33249195
[TBL] [Abstract][Full Text] [Related]
31. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
Tao Z; Cui Y; Xu X; Han T
Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
[TBL] [Abstract][Full Text] [Related]
32. The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice.
Li Q; Zhao Q; Zhang C; Zhang P; Hu A; Zhang L; Schroder PM; Ma Y; Guo Z; Zhu X; He X
J Physiol Biochem; 2018 May; 74(2):247-260. PubMed ID: 29468415
[TBL] [Abstract][Full Text] [Related]
33. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
[TBL] [Abstract][Full Text] [Related]
34. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
35. Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis.
Wu X; Li Y
Aging (Albany NY); 2009 Dec; 1(12):1023-7. PubMed ID: 20157585
[TBL] [Abstract][Full Text] [Related]
36. FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells.
Wang J; Zhao H; Zheng L; Zhou Y; Wu L; Xu Y; Zhang X; Yan G; Sheng H; Xin R; Jiang L; Lei J; Zhang J; Chen Y; Peng J; Chen Q; Yang S; Yu K; Li D; Xie Q; Li Y
Theranostics; 2021; 11(10):5045-5060. PubMed ID: 33754043
[No Abstract] [Full Text] [Related]
37. Monomeric/dimeric forms of Fgf15/FGF19 show differential activity in hepatocyte proliferation and metabolic function.
Williams CM; Harper Calderon J; E H; Jimenez Y; Barringer K; Carbonaro M; Molina-Portela MDP; Thurston G; Li Z; Daly C
FASEB J; 2021 Feb; 35(2):e21286. PubMed ID: 33484478
[TBL] [Abstract][Full Text] [Related]
38. Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.
Lang L; Teng Y
Cells; 2019 Jan; 8(1):. PubMed ID: 30634399
[TBL] [Abstract][Full Text] [Related]
39. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.
Wu AL; Coulter S; Liddle C; Wong A; Eastham-Anderson J; French DM; Peterson AS; Sonoda J
PLoS One; 2011 Mar; 6(3):e17868. PubMed ID: 21437243
[TBL] [Abstract][Full Text] [Related]
40. The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.
Drafahl KA; McAndrew CW; Meyer AN; Haas M; Donoghue DJ
PLoS One; 2010 Dec; 5(12):e14412. PubMed ID: 21203561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
